Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
When using liquid colors for coloring plastics, beside peristaltic pumps also other dosing systems are used whose pump h…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor t…
Three performance levels for injection vials, syringes, ampoules and cartridges Clear and consistent structure for s…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially a…